The abstract for this article was presented by Dr. Mauricio Cohen at TCT 2015
and reported by the Protected PCI blogging team during the conference.
Cohen, et al. (2015) compared the experiences of high-risk PCI patients in the PROTECT II clinical trial with a similar group of patients treated in certain “real world” clinical settings. Patients enrolled in the now global cVAD Registry™ (formerly USpella) comprised the “real world” patient groups.Continue readingReal-World Data Show Protected PCI Patients Had Significant CHF Symptom Improvement at Discharge
Today at TCT, an abstract by Dr. Mauricio Cohen of University of Miami Medical Center was discussed during a poster session. The data, which was published online in a paper in the American Heart Journal
on August 15, 2015, included the largest cohort of complex high-risk PCI patients supported by the Impella 2.5 in real-world practice and in clinical trials. The data demonstrated that clinical trial results mirror real world experience in the use of high risk PCI with pVADs.A new development discussed was the transition of the USpella registry to the now global, cVAD registry. The cVAD registry will include patients treated with all of the devices within the Impella platform and currently includes 2,655 patients enrolled from 47 sites.Continue readingReal-World Data Mirror Clinical Trial Results for Impella Use in High-Risk PCI